Text Size
S
M
L
Listen
Santen Global
menu
Patients
Healthcare Professionals
Careers
Investors
Listen
Tap on the left to use.
Who We Are
Message
Message from the CEO
Corporate Story
Corporate Story
CORE PRINCIPLE / Our Commitment
CORE PRINCIPLE / Our Commitment
Our Values
Our Values
History
History of Santen
Corporate Executives
Corporate Executives
Corporate Governance
Corporate Governance
Policies
Policies and Statements
Company Infomation
Overview / Map
Global Operation
What We Do
MTP & Santen 2030
Medium-term Management Plan
Santen 2030
Efforts to Enhance Patients' Satisfaction
Efforts to Enhance Product Safety
Efforts to Enhance Product Usability
Efforts to Address Untreated Patients
Research & Development
Research & Development
The Ophthalmic Product Process: R&D
Clinical Trial Information
Partnering
Santen's Partnership
Our Partners
Partnering Contact
Production
Production
Quality Compliance
The Ophthalmic Production Process: Production
Sales & Marketing
Sales & Marketing
Our Stories
Sustainability
Our Sustainability Commitment
Our Sustainability Commitment
Sustainability at Santen
Sustainability at Santen
Social
Access to Healthcare
Research & Development in Ophthalmology
Product Quality & Safety
Supply Chain
Human Rights
Talent
Digital Transformation (DX)
Governance
Corporate Governance
Compliance
Ethical Marketing
Risk Management
Environment
Environmental initiatives
Measures against Climate Change
Environmental Load Reduction
Disclosures Based on the TCFD Recommendations
Inclusion
Inclusive Society Santen Promotes
Inclusion Starting from Blind Football
Together with Society
With Employees
Related Information
Participating in the UN Global Compact
Social Contribution Activities
Stakeholder Engagement
Environment Data (up-to-date)
Social Data (up-to-date)
Governance Data (up-to-date)
GRI Standards Content Index
Sustainability Library
External Assessment
News
News
Show All
Press Release
IR News
Information
HOME
News
News
Press Release
IR News
Information
Press Release
04.17.2024
Santen and Bayer Yakuhin Launch Ophthalmic VEGF Inhibitor Eylea®8mg Solution for Intravitreal Injection 114.3 mg/mL
04.16.2024
Santen Positioned for Further Growth in China Following Completion of Santen Vision Park
03.26.2024
Santen obtains manufacturing and marketing approval in Japan for Alesion® eyelid cream (epinastine hydrochloride), a new treatment for allergic conjunctivitis
03.25.2024
Santen Announces Change of Representative Director of the Board
03.11.2024
Notice of Corporate Officer Changes
Press Release
IR News
04.17.2024
Santen and Bayer Yakuhin Launch Ophthalmic VEGF Inhibitor Eylea®8mg Solution for Intravitreal Injection 114.3 mg/mL
04.16.2024
Santen Positioned for Further Growth in China Following Completion of Santen Vision Park
03.26.2024
Santen obtains manufacturing and marketing approval in Japan for Alesion® eyelid cream (epinastine hydrochloride), a new treatment for allergic conjunctivitis
03.25.2024
Santen Announces Change of Representative Director of the Board
03.25.2024
Santen Announces Cancellation of Treasury Shares
IR News
Information
01.23.2024
Website Restoration Notice
01.15.2024
Santen Providing Disaster Relief to Communities Impacted by 2024 Noto Peninsula Earthquake
11.30.2023
Notice Regarding Closure of Official Facebook and X Accounts
02.07.2023
Santen selected as "The Sustainability Yearbook Member" by S&P Global in the United States
06.29.2022
Disclosures based on the TCFD recommendations has published
Information
News Archive
